The article linked below shows that overexpression of phosphoenolpyruvate carboxykinase (GTP) (PEPCK-C) in skeletal muscle leads to supercharged mice capable of running long distances and having a great longevity. What is there to stop humans from having gene therapy to increase expression of (PEPCK-C) in skeletal muscles and how do you ensure that this will not happen or happening. Good by EPO and welcome the new wave of performance enhancement, gene therapy.
http://www.jbc.org/content/282/45/32844.full
No comments:
Post a Comment